Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim

Last Updated: October 19, 2019

DrugPatentWatch Database Preview

Details for Patent: 5,852,195

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 5,852,195 protect, and when does it expire?

Patent 5,852,195 protects APTIVUS and is included in two NDAs.

Protection for APTIVUS has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has fifty-two patent family members in thirty-one countries.

Summary for Patent: 5,852,195
Title: Pyranone compounds useful to treat retroviral infections
Abstract:The present invention relates to compounds of formulae (I) and (II) which are pyran-2-ones, 5,6-dihydro-pyran-2-ones, 4-hydroxy-benzopyran-2-ones, 4-hydroxy-cycloalkyl[b]pyran-2-ones, and derivatives thereof, useful for inhibiting a retrovirus in a mammalian cell infected with said retrovirus, wherein R.sub.10 and R.sub.20 taken together are formulae (III) and (IV). ##STR1##
Inventor(s): Romines; Karen Rene (Paw Paw, MI), Bundy; Gordon L. (Portage, MI), Schwartz; Theresa M. (Kalamazoo, MI), Tommasi; Ruben A. (Whitehouse Station, NJ), Strohbach; Joseph W. (Mendon, MI), Turner; Steven Ronald (Kalamazoo, MI), Thaisrivongs; Suvit (Kalamazoo, MI), Aristoff; Paul Adrian (Kalamazoo, MI), Johnson; Paul D. (Portage, MI), Skulnick; Harvey Irving (Kalamazoo, MI), Skaletzky; Louis L. (Kalamazoo, MI), Anderson; David John (Kalamazoo, MI), Morris; Joel (Kalamazoo, MI), Gammill; Ronald B. (Portage, MI), Luke; George P. (Lexington, MA)
Assignee: Pharmacia & Upjohn Company (Kalamazoo, MI)
Application Number:08/809,224
Patent Claim Types:
see list of patent claims

Drugs Protected by US Patent 5,852,195

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Boehringer Ingelheim APTIVUS tipranavir CAPSULE;ORAL 021814-001 Jun 22, 2005 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Boehringer Ingelheim APTIVUS tipranavir SOLUTION;ORAL 022292-001 Jun 23, 2008 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 5,852,195

PCT Information
PCT FiledMay 04, 1995PCT Application Number:PCT/US95/05219
PCT Publication Date:November 16, 1995PCT Publication Number: WO95/30670

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.